IBA S.A. and ScandiDos A.B. announced that they have formed a strategic alliance for radiation therapy dosimetry solutions. The collaboration will enable the two businesses to work together on product development, marketing and product distribution in selected markets, for patient quality assurance for radiotherapy. Specifics of the collaboration will be developed jointly by the parties in the coming months.

IBA Dosimetry and ScandiDos have secured this collaboration as part of their shared vision for a complete radiotherapy quality assurance solution. By combining the portfolios of both companies, IBA Dosimetry and ScandiDos can accomplish this vision, offering an increasingly extensive suite of products that provide a consistent solution for all aspects of radiotherapy quality assurance. Under the terms of the agreement, IBA will purchase the full share issue (4,150,000 shares) made by ScandiDos on 30 August at a price of SEK 3.00, corresponding to an 8% premium on the average of the company's last 12 month's trading on the Stockholm stock exchange.

Following the transaction IBA will hold 9.1% of ScandiDos A.B.'s share capital.